Drug helps patients with relapsed myeloma

BMJ 2003; 327 doi: (Published 03 July 2003) Cite this as: BMJ 2003;327:7
  1. Janice Hopkins Tanne
  1. New York

    Bortezomib, the first of a new class of drugs called proteasome inhibitors, produced a 35% response rate in patients with relapsed, refractory multiple myeloma, an unusually high rate in these patients, for whom there is no other treatment.

    A phase II study published in the New England Journal of Medicine (2003;348: 2609-17 led the US Food and Drug Administration to grant accelerated approval to Millennium Pharmaceuticals to provide the drug to patients whose disease …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription